ArticleSouth Asian journal of cancer2025

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India.

Atul Tiwari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.